Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 13, 2026 01:15 ET | Source: Novartis Pharma AG

Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy

In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1Results favored Vanrafia across multiple...
February 06, 2026 12:00 ET | Source: Novartis Pharma AG

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel,...
February 06, 2026 12:00 ET | Source: Novartis Pharma AG

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel,...
February 04, 2026 01:00 ET | Source: Novartis Pharma AG

Novartis erzielte im Jahr 2025 eine Umsatzsteigerung im hohen einstelligen Prozentbereich, eine Kerngewinnmarge von 40% sowie weitere Fortschritte in der Pipeline

Ad-hoc-Mitteilung gemäss Art. 53 KRGeschäftsjahrDer Nettoumsatz wuchs um +8% (kWk1, +8% USD), das operative Kernergebnis1 verbesserte sich um +14% (kWk, +12% USD)Das Umsatzwachstum beruhte auf...
February 04, 2026 01:00 ET | Source: Novartis Pharma AG

Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025

Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +8% (cc1, +8% USD) with core operating income1 up +14% (cc, +12% USD) Sales growth driven by continued strong performance from...
January 16, 2026 12:00 ET | Source: Novartis Pharma AG

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1Distinction expedites development and review of treatments for serious...
January 09, 2026 10:30 ET | Source: Novartis Pharma AG

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern USPurpose-built facility will strengthen Novartis RLT...
January 09, 2026 10:30 ET | Source: Novartis Pharma AG

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern USPurpose-built facility will strengthen Novartis RLT...
December 19, 2025 14:30 ET | Source: Novartis Pharma AG

Novartis and US government reach agreement on lowering drug prices in the US

Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricingAdditional Novartis medicines will be made available through direct-to-patient platforms in 2026Company...
December 12, 2025 07:00 ET | Source: Novartis Pharma AG

Novartis breaks ground on flagship manufacturing hub in North Carolina

FDA Commissioner Marty Makary, North Carolina Governor Josh Stein and Novartis leadership highlight importance of new hub to US patients and local economyConstruction reflects company’s commitment to...